title: Effects of TS-1 on peritoneal dissemination of gastric cancer in nude mice.
abstract: OBJECTIVE
  We investigated the effects of TS-1 on the survival of nude mice developing peritoneal dissemination of gastric cancer.
  
  
  METHODS
  MKN-45 cells were injected into the peritoneal cavity of nude mice and a model of peritoneal dissemination was developed. TS-1 was administered orally every day from day 1 to day 10 or day 10 to day 19.
  
  
  RESULTS
  Survival time of these treatment groups was significantly longer than untreated controls. In a pharmacokinetic study, TS-1 was administered on day 10 and the 5-fluorouracil levels were retained and maintained for a longer time, in the ascites and tumor than in plasma. The area under the concentration curve for 5-FU in the tumor was higher, than in plasma or ascites.
  
  
  CONCLUSIONS
  TS-1 could be effective in treating peritoneal dissemination of gastric cancer, due to the supply of 5-fluorouracil in the tumor by systemic and intraperitoneal circulation.
authors.affiliation: Department of Gastrointestinal Surgery, Research Institute Kanagawa Cancer Center, Yokohama City Kowan Hospital, Yokohama, Japan.
authors.forename: Takaki
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Yanoma
authors.forename: Akira
authors.initials: A
authors.lastname: Tsuburaya
authors.forename: Osamu
authors.initials: O
authors.lastname: Kobayashi
authors.forename: Motonori
authors.initials: M
authors.lastname: Sairenji
authors.forename: Hisahiko
authors.initials: H
authors.lastname: Motohashi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Hasegawa
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishiwa
authors.forename: Soichiro
authors.initials: S
authors.lastname: Morinaga
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Akihiko
authors.initials: A
authors.lastname: Matsumoto
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001682:Biological Availability; D045744:Cell Line, Tumor / Q000473:pathology; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000097:blood; D004347:Drug Interactions; D005472:Fluorouracil / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000556:secondary*; D010537:Peritoneum / Q000473:pathology; D017640:Silicates / Q000494:pharmacology*; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000473:pathology*; D016019:Survival Analysis; D014025:Titanium / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D017640:Silicates; C103828:titanium silicide; D014025:Titanium; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil